Enhanced antitumor efficacy of sorafenib and everolimus combination in pancreatic neuroendocrine neoplasms through mTOR inhibition.

ABSTRACT:

Background

Pancreatic neuroendocrine neoplasms (pNENs) represent a rare group of highly heterogeneous tumors derived from pancreatic epithelial cells exhibiting neuroendocrine differentiation properties. Everolimus, an oral inhibitor of mTOR, is the most promising drug for patients with unresectable, metastatic disease, particularly in progressive well-differentiated pNENs. Sorafenib is utilized in the treatment of hepatocellular carcinoma (HCC), renal cell carcinoma, and differentiated thyroid cancer. Furthermore, it plays an indispensable role in the management of multisystem malignancies. This study aims to investigate the effects and mechanisms of sorafenib, as well as its potential for combination use with everolimus in pNENs.

Methods

QGP-1and BON-1cells were collected

SUBMITTER: Zheng H 

PROVIDER: S-EPMC12432615 | biostudies-literature | 2025 Aug

REPOSITORIES: biostudies-literature